e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
IPF: from bench to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Paola Faverio (Limbiate, Italy), Paola Faverio, Roberto Ruggiero, Valentina Paolini, Luca Novelli, Federica De Giacomi, Alice Biffi, Elisa Oggionni, Luca Bilucaglia, Alberto Pesci
Source:
International Congress 2015 – IPF: from bench to bedside
Session:
IPF: from bench to bedside
Session type:
Poster Discussion
Number:
3045
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Paola Faverio (Limbiate, Italy), Paola Faverio, Roberto Ruggiero, Valentina Paolini, Luca Novelli, Federica De Giacomi, Alice Biffi, Elisa Oggionni, Luca Bilucaglia, Alberto Pesci. Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2015; 46: Suppl. 59, 3045
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Lane-hamilton syndrome and CCF: a fatal association
Related content which might interest you:
High-dose acetylcysteine in idiopathic pulmonary fibrosis
Source: ISSN=ISSN 1810-6838, ISBN=, page=358
Year: 2006
Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses
Source: Eur Respir J 2011; 38: 1487-1489
Year: 2011
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
Source: Eur Respir J 2005; 25: 528-533
Year: 2005
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020
Year: 2020
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Pulse therapy of corticosteroids in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
Acute exacerbation of idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 23: 792
Year: 2004
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2016 – Russia Session
Year: 2016
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Idiopathic pulmonary haemosiderosis revisited
Source: Eur Respir J 2004; 24: 162-169
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept